Given that our findings demonstrate the prognostic association between BCR and OS and the relative importance of noncancer-related deaths and cancer-specific deaths in nonmetastatic PCa, BCR is clearly not an ideal end point for biomarker development or validation in general. The gene discussed is BCR; the disease is posterior cortical atrophy.